首页> 外文OA文献 >Treatment of Recurrent Posttransplant Lymphoproliferative Disorder with Autologous Blood Stem Cell Transplant
【2h】

Treatment of Recurrent Posttransplant Lymphoproliferative Disorder with Autologous Blood Stem Cell Transplant

机译:用自体血液干细胞移植治疗复发性后翻转淋巴抑制性疾病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Background. Posttransplant lymphoproliferative disorders (PTLDs) occur after solid organ transplantation. Treatment guidelines include reduction in immunosuppression (RIS), radiation, rituximab, chemotherapy, and immunological agents. We present a rare case of recurrent diffuse large B-cell lymphoma presenting as a PTLD in a heart transplant patient treated with autologous blood stem cell transplant (ASCT) after failure of conventional therapy. Case Presentation. A 66-year-old male presented with a neck mass. He has a history of Hodgkin’s disease status after staging laparotomy with splenectomy and heart transplantation due to dilated nonischemic cardiomyopathy 8 years prior to the development of PTLD. His examination was remarkable for right submandibular swelling. An excisional biopsy confirmed the diagnosis of diffuse large B-cell NHL. Patient received RIS, rituximab, chemotherapy, and radiation therapy with a complete remission. His lymphoma relapsed and he subsequently was treated with RICE salvage chemotherapy and consolidative high-dose chemotherapy with BEAC regimen followed by ASCT resulting in a complete remission. Conclusion. Patients with PTLD present a difficult therapeutic challenge. In this case, the patient’s prior history of Hodgkin’s disease, splenectomy, and a heart transplant appear to be unique features, the significance of which is unclear. ASCT might be a promising therapy for patients with relapsed or refractory PTLD.
机译:背景。固体器官移植后发生后翻转淋巴抑制性疾病(PTLD)。治疗指南包括减少免疫抑制(RIS),辐射,利妥昔单抗,化学疗法和免疫试剂。我们在常规治疗失败后,呈现罕见的散射大型B细胞淋巴瘤在用自体血液干细胞移植(ASCT)处理后的心脏移植患者中的PTLD。案例演示。一名66岁的男性呈现出颈部质量。他在PTLD发育前8年之前患有脾脏切除术和心脏移植的肺切除术和心脏移植后,他有霍奇金皮病状态的历史。他的检查对于正确的颌下肿胀是显着的。促进活检证实弥漫性大B细胞NHL的诊断。患者接受RIS,RITUXIMAB,化疗和放射治疗,完全缓解。他的淋巴瘤复发了,随后他用大米救助化疗和与BEAC方案进行的共同化高剂量化疗进行治疗,然后由ASCT产生完全缓解。结论。患有PTLD的患者存在难以治疗的挑战。在这种情况下,患者的霍奇金氏病,脾切除术病史,脾切除术病史似乎是独特的特征,其意义尚不清楚。 ASCT可能是对复发或难治性PTLD患者的有希望的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号